The next wave of metabolic medicines in development includes oral GLP-1 drugs that work comparably to currently available injectable medicines, and Eli Lilly is taking the lead with Phase 3 ...

Eli Lilly's rapid growth has been linked to its deep and varied roster of leading pharmaceutical products, including Trulicity and Mounjaro (treatments for diabetes) and Prozac and Cymbalta ...